SecBot SecBot
8-K ·Filed Jun 4, 2026

FATE

FATE THERAPEUTICS INC
NEUTRAL
Impact 4/10
Horizonweeks Processed5mo ago SEC0001193125-26-257558
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

This is a routine corporate presentation update with no new material financial data. Key catalyst to watch is the initiation of the RECLAIM-LN Phase 2 trial in 2H 2026 and FT839 IND filing, both binary clinical events. Monitor for patient enrollment updates and potential partnership announcements given the cash runway guidance into 2028.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.98
T+0 close · Jun 4, 2026 · via day close
Latest settled
+20.71%
T+60 · $2.39
Vs SPY
+16.71%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 5 $1.98entry
  2. T+1 · 5mo ago −3.54%α −3.76% · $1.91
  3. T+5 · 5mo ago +4.04%α +3.47% · $2.06
  4. T+20 · 4mo ago +51.01%α +49.15% · $2.99
  5. T+60 · 3mo ago +20.71%α +16.71% · $2.39

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fate Therapeutics filed an 8-K on June 4, 2026, to update its corporate presentation for the EULAR 2026 Congress, highlighting Phase 1 data for FT819 in autoimmune diseases and the upcoming Phase 2 RECLAIM-LN registrational trial in lupus nephritis. The filing also included Q1 2026 financials showing $174.8M cash runway into 2028 and a 20% YoY OpEx reduction, but the primary content is a routine corporate update without new material financial disclosures.

Key Facts

  • Corporate presentation updated for EULAR 2026 Congress on June 4, 2026.
  • FT819-102 Phase 1 data: 26 patients dosed (22 SLE, 4 SSc, 3 IIM, 1 AAV); 21 activated clinical sites; 8 patients treated in outpatient settings.
  • FT819-102 demonstrated no DLT, no Grade >2 CRS, ICANS, GvHD or deaths in 16 SLE Regimen A patients.
  • RECLAIM-LN Phase 2 potentially registrational trial for lupus nephritis planned to begin patient dosing in 2H 2026 with 53-patient enrollment targeting BLA submission in 2028.
  • Q1 2026 cash and short-term investments of $174.8M, with cash runway into 2028.
  • Total OpEx reduction of 20% YoY in Q1 2026, with R&D down 15% and G&A down 30%.
  • Weighted-average shares outstanding of 120.0M.
  • FT839 IND filing planned 2H 2026; FT839 Phase 1 pan-autoimmune trial initiation 2H 2026.

Financial Impact

Cash runway into 2028 with $174.8M cash and investments; no revenue or EPS reported in filing.

cashcash runwayoperating expenses

Risk Factors

  • Clinical trial execution risk for RECLAIM-LN Phase 2 enrollment timelines and outcomes.
  • Regulatory risk: FT819's registrational path depends on alignment with FDA, which may shift timelines.
  • Cash runway into 2028 provides buffer but ongoing R&D spend without revenue creates dilution risk.
  • Competition in off-the-shelf CAR T-cell therapy space for autoimmune indications.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
61% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-257558
Document: d83385d8k.htm0001193125-26-257558
Document: 0001193125-26-257558-index-headers.html0001193125-26-257558
Document: 0001193125-26-257558-index.html0001193125-26-257558
Document: 0001193125-26-257558.txt0001193125-26-257558

Track record

21 reports on FATE

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  2. Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  3. Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
  4. Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
  5. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  6. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  7. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  8. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
  9. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
  10. Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 8h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 4, 2026